International Society of Liquid Biopsy shared a post on X:
“ISLB-Endorsed Seminar: The Evolving Role of Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer.
Expert Insights from:
- Prof. Frédérique Penault-Llorca (Pathologist, Univ. of Clermont-Ferrand, France).
- Dr. Aditya Bardia (Medical Oncologist, UCLA, USA).
Key Takeaways:
- Liquid biopsy complements tumor biopsy for molecular profiling.
- Detects critical mutations (ESR1, PIK3CA) linked to therapy resistance.
- NGS testing follows ESMO & NCCN guidelines for precision medicine.
- Endorsed by ISLB, this seminar highlights the latest advances in biomarker testing & patient management!
Watch now.”